-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the context of the accelerated development of China's innovative drug industry, major pharmaceutical companies have begun to increase their R&D layout in the field of innovative drugs
.
It is worth mentioning that in order to accelerate the development and commercialization of innovative drugs, cooperation between pharmaceutical companies on innovative drugs is also increasing
.
It is understood that since November, many pharmaceutical companies have announced that they will cooperate with other companies in drug development and commercialization
.
On November 11, Hengrui Pharmaceuticals announced that it has reached a cooperation with CStone Pharmaceuticals to introduce the anti-CTLA-4 monoclonal antibody CS1002
.
According to the announcement, Hengrui Pharmaceuticals will pay about 1.
3 billion yuan in advance and milestone payments to CStone Pharmaceuticals, as well as royalties that are a double-digit percentage of annual net sales after the product is launched.
Exclusive rights for registration, production and commercialization
.
It is worth noting that this is the fourth BD move made public by Hengrui Medicine since the second half of this year
.
The industry believes that the apparently accelerated pace of foreign cooperation is a manifestation of Hengrui Medicine's recent efforts in innovative drugs
.
In addition to Hengrui, on November 11, Jichuan Pharmaceutical also issued an announcement, announcing that it has reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan)
.
Jichuan Pharmaceutical will pay an advance payment of 224 million yuan to Tianjing Bio, and follow-up payment of a milestone payment of not more than 1.
792 billion yuan, with a total payment of 2.
016 billion yuan
.
After the strategic cooperation, Tianjing Bio will continue to lead the phase III clinical trials of Etan growth hormone for the treatment of children's growth hormone deficiency, as well as the production, continuous process optimization and the development of new formulations, and submit it as an applicant for the listing of Etan growth hormone.
License registration application to supply medicine to Jichuan Pharmaceutical
.
Jichuan Pharmaceutical will participate in the cooperation, share the cost, be responsible for expanding other new indications of Etan growth hormone, and be responsible for the commercialization of the product in the Chinese market after the product is approved.
Tianjing Bio will be responsible for clinical, production and academic aspects.
provide support
.
In addition, on November 3, Aoxiang Pharmaceuticals signed a "Cooperative Development and Commercialization Strategic Cooperation Agreement" with STADA Arzneimittel AG (STADA") approved by the board of directors.
The two parties will focus on the future global pharmaceutical industry.
Industry development prospects, to carry out long-term comprehensive cooperation on the joint development of chemical generic pharmaceutical preparations and global marketing
.
At present, the R&D investment budget for the first phase of the selected projects of the two parties is 23.
5 million euros, and the countries in the cooperation area will be jointly borne by the two parties (50%/50%)
.
Public information shows that STADA is a global pharmaceutical company that sells its products in about 120 countries around the world
.
STADA focuses on three business areas, including generic drugs, professional pharmaceuticals and over-the-counter consumer healthcare products.
It has a wealth of experience in the development, production and sales of pharmaceutical products
.
Through this cooperation, it will help promote the internationalization of Aoxiang Pharmaceutical's preparations and enhance the internationalization of the company's preparations
.
From an overall point of view, in fact, since the beginning of this year, cooperation and exchanges between domestic pharmaceutical companies and Chinese and foreign pharmaceutical companies have been very frequent, and acquisitions and strategic cooperation have continued
.
In this regard, the industry believes that, according to current trends, in order to accelerate the development and commercialization of innovative drugs, cooperation between domestic pharmaceutical companies on innovative drugs will continue to increase
.
Among them, it is worth noting that domestic companies with strong R&D capabilities, especially those focusing on research and development in a certain disease field, as well as drug declaration capabilities and excellent drug commercialization capabilities, may become the main initiators of cooperation in the future
.
.
It is worth mentioning that in order to accelerate the development and commercialization of innovative drugs, cooperation between pharmaceutical companies on innovative drugs is also increasing
.
It is understood that since November, many pharmaceutical companies have announced that they will cooperate with other companies in drug development and commercialization
.
On November 11, Hengrui Pharmaceuticals announced that it has reached a cooperation with CStone Pharmaceuticals to introduce the anti-CTLA-4 monoclonal antibody CS1002
.
According to the announcement, Hengrui Pharmaceuticals will pay about 1.
3 billion yuan in advance and milestone payments to CStone Pharmaceuticals, as well as royalties that are a double-digit percentage of annual net sales after the product is launched.
Exclusive rights for registration, production and commercialization
.
It is worth noting that this is the fourth BD move made public by Hengrui Medicine since the second half of this year
.
The industry believes that the apparently accelerated pace of foreign cooperation is a manifestation of Hengrui Medicine's recent efforts in innovative drugs
.
In addition to Hengrui, on November 11, Jichuan Pharmaceutical also issued an announcement, announcing that it has reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan)
.
Jichuan Pharmaceutical will pay an advance payment of 224 million yuan to Tianjing Bio, and follow-up payment of a milestone payment of not more than 1.
792 billion yuan, with a total payment of 2.
016 billion yuan
.
After the strategic cooperation, Tianjing Bio will continue to lead the phase III clinical trials of Etan growth hormone for the treatment of children's growth hormone deficiency, as well as the production, continuous process optimization and the development of new formulations, and submit it as an applicant for the listing of Etan growth hormone.
License registration application to supply medicine to Jichuan Pharmaceutical
.
Jichuan Pharmaceutical will participate in the cooperation, share the cost, be responsible for expanding other new indications of Etan growth hormone, and be responsible for the commercialization of the product in the Chinese market after the product is approved.
Tianjing Bio will be responsible for clinical, production and academic aspects.
provide support
.
In addition, on November 3, Aoxiang Pharmaceuticals signed a "Cooperative Development and Commercialization Strategic Cooperation Agreement" with STADA Arzneimittel AG (STADA") approved by the board of directors.
The two parties will focus on the future global pharmaceutical industry.
Industry development prospects, to carry out long-term comprehensive cooperation on the joint development of chemical generic pharmaceutical preparations and global marketing
.
At present, the R&D investment budget for the first phase of the selected projects of the two parties is 23.
5 million euros, and the countries in the cooperation area will be jointly borne by the two parties (50%/50%)
.
Public information shows that STADA is a global pharmaceutical company that sells its products in about 120 countries around the world
.
STADA focuses on three business areas, including generic drugs, professional pharmaceuticals and over-the-counter consumer healthcare products.
It has a wealth of experience in the development, production and sales of pharmaceutical products
.
Through this cooperation, it will help promote the internationalization of Aoxiang Pharmaceutical's preparations and enhance the internationalization of the company's preparations
.
From an overall point of view, in fact, since the beginning of this year, cooperation and exchanges between domestic pharmaceutical companies and Chinese and foreign pharmaceutical companies have been very frequent, and acquisitions and strategic cooperation have continued
.
In this regard, the industry believes that, according to current trends, in order to accelerate the development and commercialization of innovative drugs, cooperation between domestic pharmaceutical companies on innovative drugs will continue to increase
.
Among them, it is worth noting that domestic companies with strong R&D capabilities, especially those focusing on research and development in a certain disease field, as well as drug declaration capabilities and excellent drug commercialization capabilities, may become the main initiators of cooperation in the future
.
